News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
UK’s NICE Backs First-line Use of Johnson & Johnson’s Velcade
June 2, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Britain's healthcare cost-effectiveness watchdog NICE recommended Johnson & Johnson's (JNJ.N) drug Velcade as a first-line treatment for multiple myeloma in draft guidance issued on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
Obesity
Obesity Space Abuzz With Oral, Amylin Assets as Momentum Rides Into 2026
February 6, 2026
·
4 min read
·
Mark Zipkin
Insights
Programmable RNA 2.0: Beyond the First mRNA Revolution
February 5, 2026
·
1 min read
·
Jennifer Smith-Parker
Duchenne muscular dystrophy
Sarepta Saga Has ‘Gone on Too Long’ as Competitors Catch Up
February 5, 2026
·
5 min read
·
Dan Samorodnitsky
Immunology and inflammation
Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I
February 4, 2026
·
2 min read
·
Heather McKenzie
